Adherium launched its digital inhaler add-on in the U.S., following a recent 510(k) clearance allowing it to sell the devices directly to consumers.

Former Fierce 15 winner MaxQ plans to go public with $8 million IPO, as it awaits FDA approval of its AI tech for analyzing CT scans for brain bleeds.

Senseonics’ long-term CGM is now available in clinics across the U.S. and has secured its first commercial payer.

Akili brought its series C total up to $68 million while it awaits an FDA decision on its prescription video game for pediatric ADHD.

Agilent’s PD-L1 assay was expanded in Europe to help guide first-line Keytruda treatment in urothelial carcinoma.

Boston Scientific is acquiring the remainder of Veniti for $108 million upfront, plus up to $52 million pending approval of its Vici venous stent.

Credence MedSystems received a shot of $12.8 million in financing through a series B round.

Sensyne Health plans to go public with a £60 million listing ($77 million) on the London Stock Exchange on Aug. 17.

Certara said its software supported 95% of the 20 novel FDA approvals from the first half of this year, as the agency aims to modernize its reviews.